The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Insulin Resistance as a Shared Pathogenic Mechanism Between Depression and Type 2 Diabetes
Open accessAbstract
Neuropsychiatric disorders and type 2 diabetes (T2D) are major public health concerns proposed to be intimately connected. T2D is associated with increased risk of dementia, neuropsychiatric and mood disorders. Evidences of the involvement of insulin signaling on brain mechanisms related to depression indicate that insulin resistance, a hallmark of type 2 diabetes, could develop in the brains of depressive patients. In this article, we briefly review possible molecular mechanisms associating defective brain insulin signaling with reward system, neurogenesis, synaptic plasticity and hypothalamic-pituitary-adrenal (HPA) stress axis in depression. We further discuss the involvement of tumor necrosis factor α (TNFα) promoting defective insulin signaling and depressive-like behavior in rodent models. Finally, due to the high resistant rate of anti-depressants, novel insights into the link between insulin resistance and depression may advance the development of alternative treatments for this disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vos, T., Barber, R. M., Bell, B., Bertozzi-Villa, A., Biryukov, S., Bolliger, I., Charlson, F., Davis, A., Degenhardt, L., Dicker, D., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60692-4 · Cited by 6,414
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652 · cited 1×
“Metformin is a commonly used treatment for T2D with mechanisms of action not fully understood, but it involves key regulators of cellular energy status, including mitochondrial proteins and the AMP kinase (AMPK) (101, 102).”
BackgroundRush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Hearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
Role of Brain Insulin Receptor in Control of Body Weight and Reproduction
Brüning, J. C., Gautam, D., Burks, D. J., Gillette, J., Schubert, M., Orban, P. C., Klein, R., Krone, W., Müller-Wieland, D., & Kahn, C. R. (2000) · Science · doi:10.1126/science.289.5487.2122 · Cited by 2,235
Talbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59903 · Cited by 1,871
JACOBSON, L., & SAPOLSKY, R. (1991) · Endocrine Reviews · doi:10.1210/edrv-12-2-118 · Cited by 1,739
Raison, C. L., Rutherford, R. E., Woolwine, B. J., Shuo, C., Schettler, P., Drake, D. F., Haroon, E., & Miller, A. H. (2013) · JAMA Psychiatry · doi:10.1001/2013.jamapsychiatry.4 · Cited by 1,617 · cited 1×
“However, in patients with a higher inflammatory state, indicated by serum C-Reactive protein (CRP) concentration higher than 5 mg/L, infliximab improved HAM-D scores compared to placebo (117).”
BackgroundDepression and Type 2 Diabetes Over the Lifespan
Mezuk, B., Eaton, W. W., Albrecht, S., & Golden, S. H. (2008) · Diabetes Care · doi:10.2337/dc08-0985 · Cited by 1,558
Glucose Transporters and Insulin Action — Implications for Insulin Resistance and Diabetes Mellitus
Shepherd, P. R., & Kahn, B. B. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907223410406 · Cited by 1,295
Cited by
The Antidepressant Effects of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis
Chen, X., Zhao, P., Wang, W., Guo, L., & Pan, Q. (2024) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2023.08.010 · Cited by 185
The Impact of Type 2 Diabetes in Parkinson's Disease
Athauda, D., Evans, J., Wernick, A., Virdi, G., Choi, M. L., Lawton, M., Vijiaratnam, N., Girges, C., Ben‐Shlomo, Y., Ismail, K., et al. (2022) · Movement Disorders · doi:10.1002/mds.29122 · Cited by 132
Och, A., Och, M., Nowak, R., Podgórska, D., & Podgórski, R. (2022) · Molecules · doi:10.3390/molecules27041351 · Cited by 104
Allostasis, action and affect in depression: Insights from the theory of constructed emotion
Shaffer, C., Westlin, C., Quigley, K. S., Whitfield-Gabrieli, S., & Barrett, L. F. (2022) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-081219-115627 · Cited by 94
Association between anxiety and depression and nonalcoholic fatty liver disease
Choi, J. M., Chung, G. E., Kang, S. J., Kwak, M.-S., Yang, J. I., Park, B., & Yim, J. Y. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2020.585618 · Cited by 68
Jiang, F.-H., Liu, X.-M., Yu, H.-R., Qian, Y., & Chen, H.-L. (2022) · The International Journal of Lower Extremity Wounds · doi:10.1177/1534734620929892 · Cited by 65
Chen, D., Zhang, Y., Huang, T., & Jia, J. (2023) · Psychological Medicine · doi:10.1017/s0033291723000867 · Cited by 52
Macchi, C., Favero, C., Ceresa, A., Vigna, L., Conti, D. M., Pesatori, A. C., Racagni, G., Corsini, A., Ferri, N., Sirtori, C. R., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01158-6 · Cited by 51
Depression, antidepressants, and insulin resistance: which link?
Fanelli, G., & Serretti, A. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.04.011 · Cited by 39
Endocrine factors in key structural and intracellular changes in depression
Gold, P. W. (2021) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2021.01.003 · Cited by 35
Rashidian, H., Subramaniapillai, M., Park, C., Lipsitz, O., Zuckerman, H., Cao, B., Lee, Y., Gill, H., Rodrigues, R. N., Di Vincenzo, J. D., et al. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811221132473 · Cited by 23
“As previously discussed, higher baseline IR is associated with more severe depression (Lyra e Silva et al., 2019; Singh et al., 2019) and reduced response to treatment (Rashidian et al., 2021).”
BackgroundTeixeira, A. L., Martins, L. B., Berk, M., & Bauer, M. E. (2022) · Clinical Science · doi:10.1042/cs20211106 · Cited by 22
Depression in nonalcoholic fatty liver disease and all-cause/cause-specific mortality
Kim, D., Manikat, R., Shaikh, A., Cholankeril, G., & Ahmed, A. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14087 · Cited by 17
Moosecker, S., Pissioti, A., Leidmaa, E., Harb, M. R., Dioli, C., Gassen, N. C., Yu, S., Gazea, M., Catania, C., Anderzhanova, E., et al. (2021) · Neuroscience · doi:10.1016/j.neuroscience.2021.10.029 · Cited by 12
Metadata
- Authors
- Lyra e Silva, N. D. M., Lam, M. P., Soares, C. N., Munoz, D. P., Milev, R., & De Felice, F. G.
- Venue
- Frontiers in Psychiatry
- Publisher
- Frontiers Media SA
- Published
- 2019-02-14
- Volume
- 10
- Pages
- 57-57
- ISSN
- 1664-0640 (ISSN-L)
- OpenAlex
- W2914529824
- Cited by
- 164
- References
- 36
- FWCI
- 4.45
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.